JANSSEN ELECTS NOT TO CONTINUE AGREEMENT WITH GERON FOR IMETELSTAT

  • MPNRF | April 7, 2021

    Today Janssen announced that they would no longer be partnering with Geron on the development of Imetelstat, which was being tested for use in Myelofibrosis. According to the statement by Janssen, the pharmaceutical company “will work with Geron to transition the imetelstat program back to the company. Patients currently enrolled in the ongoing imetelstat clinical trials will continue to be supported through the respective trial protocols, including treatment and follow-up.”

    We will keep you updated as more news emerges about this and other drugs for myeloproliferative neoplasms.